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Abstract 
 
The antiviral restriction factor Interferon-induced transmembrane protein 3 (IFITM3) 
inhibits cell entry of a number of viruses and genetic diversity within IFITM3 
determines susceptibility to viral disease in humans. Using the murine 
cytomegalovirus (MCMV) model of infection, we discovered that Ifitm3 limits 
herpesvirus-associated pathogenesis without directly preventing virus replication. 
Instead, Ifitm3 promoted antiviral cellular immunity through the restriction of virus-
induced lymphopenia, apoptosis-independent NK cell death and loss of T cells. Viral 
disease in Ifitm3-/- mice was accompanied by elevated production of cytokines, most 
notably interleukin-6 (IL-6). Ifitm3 inhibited IL-6 production by myeloid cells in 
response to replicating and non-replicating virus, and also following stimulation with 
TLR ligands Poly(I:C) and CpG. Although IL-6 promoted virus-specific T cell 
responses, uncontrolled IL-6 expression in Ifitm3-/- mice triggered the loss of NK 
cells, and subsequently impaired control of MCMV replication. Thus, Ifitm3 
represents a checkpoint regulator of anti-viral immunity, which controls cytokine 
production to restrict viral pathogenesis. These data suggest the utility of cytokine-
targeting strategies in the treatment of virus-infected individuals with impaired IFITM3 
activity. 
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Introduction 
 
Antiviral immune responses elicited following acute viral infections are tightly 
regulated to limit uncontrolled immune pathology whilst ensuring adequate control of 
the primary infection. Herpesvirus infections are typically controlled by asymptomatic 
resolution of the primary infection and establishment of virus latency, where the 
adaptive immune response controls replication of reactivating virus. Thus, host innate 
and adaptive immune mechanisms work to hold herpesvirus replication in check. In 
some settings, failure in anti-viral defense during the primary infection leads to 
elevated virus replication and virus-induced disease pathology (1-3). 
 
Herpesvirus restriction of immune activation may contribute to limited pathology 
during acute infection. Indeed, a clear evolutionary advantage for herpesviruses 
exists to modulate antiviral immunity to maintain host fitness during acute infection, 
but also to facilitate persistence and the establishment of latency. The β−herpesvirus 
human cytomegalovirus (HCMV) represents a paradigm for viral immune evasion. It 
encodes numerous proteins with putative immune modulatory actions (4, 5), and 
HCMV infection profoundly influences the expression of host immune-related 
proteins (6). Studies in the murine cytomegalovirus (MCMV) model of β−herpesvirus 
infection have highlighted that CMV also exploits host immune inhibitory 
mechanisms, including the immune regulatory cytokine interleukin-10 (IL-10), to 
facilitate virus persistence (7-9). Paradoxically, both cellular (10) and viral (11) IL-10 
restrict acute pathologies in experimental models of CMV infection. Consequently, a 
delicate and important balance exists between control of acute replication, virus-
induced inflammation and virus persistence. The factors governing this balance and 
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the potential influence that host and virus genetic variation exerts on this process 
requires a better understanding. 
 
Interferon-induced transmembrane protein 3 (IFITM3) is an IFN-inducible antiviral 
restriction factor that is enriched in endosomal compartments (12). IFITM3 restricts 
endocytosis-dependent entry of diverse viruses, most notably influenza, Dengue 
Virus, West Nile Virus and HIV (13, 14). Importantly, genetic studies emphasize the 
pivotal role that IFITM3 plays in governing viral disease in humans. A number of 
polymorphisms within human IFITM3 have been identified that may potentially 
influence IFITM3 function (15). Notably, the minor rs12252-C allele in IFITM3, that 
has an allele frequency of 0.03 and 0.5 in European Caucasian and Han Chinese 
populations respectively (16, 17), is associated with impaired restriction of influenza 
replication (15, 16, 18), increased susceptibility to severe influenza-associated 
disease (16, 17) and HIV progression (19).  
 
Studies in murine infection models have highlighted a critical role for Ifitm3 in 
restricting viral pathogenesis in vivo. Iftim3-/- mice exhibit increased susceptibility to 
infection with influenza (16, 20), arthritogenic and encephalitic alphaviruses (21), 
respiratory syncytial virus (22) and West Nile Virus (23). Susceptibility is associated 
with the significant impairment of direct control of viral replication, in accordance with 
the established role for IFITM3 as an antiviral restriction factor. Interestingly, 
however, alterations in immune responses have also been described in these models 
(16, 21-23). Whilst these observations suggest a possible link between Ifitm3 and the 
regulation of antiviral immunity, the direct impact of Ifitm3 on virus replication has not 
been disentangled from any immune regulatory functions of Ifitm3. Furthermore, 
studies in influenza infection have revealed that impaired antiviral immune responses 
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in Ifitm3-/- mice can occur as a consequence of unregulated infection of immune cells 
(24, 25). 
  
Ifitm3 does not directly impinge on HCMV replication in vitro (26, 27). Consequently, 
we were intrigued to establish whether Ifitm3 influences herpesvirus pathogenesis in 
vivo. Using the MCMV model of infection, we identified that murine Ifitm3 is a critical 
checkpoint regulator of herpesvirus-induced immune pathology during acute and 
chronic infection in vivo. Consistent with observations in HCMV infection, Ifitm3 did 
not directly restrict MCMV replication, but instead acted to limit over-exuberant 
production of cytokines, in particular interleukin-6 (IL-6). Thus, Ifitm3 activity acts as a 
rheostat of antiviral immunity that determines the pathological outcome of acute 
MCMV infection. 
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Results 
 
Ifitm3 determines the primary outcome of MCMV infection 
To assess the impact of Ifitm3 on herpesvirus pathogenesis, we first infected control 
wild type (WT) and ifitm3-deficient mice with MCMV. Infection of WT mice with 3x104 
PFU salivary gland-propagated Smith strain MCMV resulted in a non-lethal infection 
(Figure. 1A) and moderate (~10%) weight loss (Figure 1B). However, Ifitm3-/- mice 
exhibited only a 60% survival, with mice succumbing to infection or being culled in 
accordance with UK Home Office guidelines regarding disease severity/weight loss, 
between 6-8 days post-infection (pi) (Figure 1A&B). Surviving Ifitm3-/- mice also 
exhibited delayed weight loss recovery still evident at 12 days post-infection (Figure 
1B). Furthermore, sub-clinical infection with an inoculum of 5x103 PFU/mouse also 
induced weight loss in Ifitm3-/- mice but not in WT mice (Figure S1A).   
 
Exacerbated MCMV-induced weight loss in Ifitm3-/- mice was accompanied by 
statistically significant higher virus load from days 4 pi in spleen (Figure 1C) and lung 
(Figure 1D) but not the liver (Figure 1E) after infection with standard inoculum (3x104 
PFU). Weight loss in Ifitm3-/- mice induced following low dose inoculum (5x103 PFU) 
also resulted in significantly increased virus load in the spleen 4 days pi (Figure 
S1B). Furthermore, 14 days after infection with standard inoculum, viral persistence 
in the salivary gland was evident in WT and Ifitm3-/- mice, but Ifitm3-/- mice harbored 
elevated virus load in this established site of persistent MCMV replication (Figure 
1F). Moreover, extensive pathology in spleens of Ifitm3-/- mice was observed 14 days 
pi (Figure 1G) with severe disruption of follicular structures evident (Figure 1H). 
Spleens were not recoverable from Ifitm3-/- mice 3 months post-infection (data not 
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shown), demonstrating the irreversible nature of organ damage. Thus, Ifitm3 
promoted host survival and control of virus replication during CMV infection.  
 
Ifitm3 does not influence MCMV cell entry or infectious virion production  
IFITM3 restricts entry of a number of RNA viruses that utilize the endocytic pathway 
during cell entry (13). However, IFITM3 does not restrict HCMV entry into fibroblasts 
and epithelial cells (26, 27), the latter of which requires endocytosis (28). Bone 
marrow chimera experiments revealed that Ifitm3 deficiency within the hematopoietic 
cell compartment was sufficient to increase virus load 4 days pi in vivo (Figure 
2A&B). Cytomegalovirus does not productively infect lymphocytes (29), and we 
detected no MCMV infection of WT or Ifitm3-/- T cells or NK cells, as determined by 
the absence of detection of the MCMV m06 early protein in vitro (data not shown). 
Interestingly, MCMV infection of M-CSF, GM-CSF and Flt3L differentiated bone 
marrow-derived myeloid cells was prevented by pretreatment with the endocytosis 
inhibitor EIPA (Figure S1C-E). Thus, we investigated whether Ifitm3 influenced 
endocytosis-dependent MCMV replication within myeloid cells. MCMV entry was 
unaffected by Ifitm3 deficiency when cells were infected at multiplicities of infection 
(MOI) that result in non-saturating infection in WT cells (MOI of 0.1 or 1, Figure 2C-H) 
or following infection with a higher MOI (MOI = 10, Figure S1F). Furthermore, Ifitm3 
had no impact on type I IFN-mediated endocytosis-dependent control of MCMV 
infection (Fig. S1G-I). Moreover, MCMV infection of primary mouse embryo 
fibroblasts (MEFs) was also unaffected by the absence of ifitm3 (Figure 2I&J). Thus, 
in contrast to influenza infection (Figure S1J), Ifitm3 did not influence infection 
efficiency of MCMV in our assays. Furthermore, productive virus replication following 
infection of all cell types examined was also unaffected by Ifitm3 deficiency (Figure 
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2K). Thus, as observed in HCMV infection (26, 27), our data suggest that Ifitm3 does 
not directly restrict MCMV cell entry and subsequent replication.  
 
Ifitm3
-/- mice exhibit exacerbated lymphopenia and increased leukocyte death 
during MCMV infection 
We investigated the mechanisms underpinning MCMV-induced pathogenesis in 
Ifitm3
-/- mice. Lymphopenia is a hallmark of severe viral disease (30). MCMV-infected 
Ifitm3
-/- mice exhibited exacerbated systemic lymphopenia and a concomitant 
elevation in circulating granulocytes during MCMV infection (Figure 3A). This was 
accompanied by a large reduction in splenocyte numbers d4 pi (Figure 3B). 
Circulating blood platelet and red blood cells were not reduced in Ifitm3-/- mice, 
suggesting that lymphopenia was not a consequence of generalized bone marrow 
suppression (Figure S2A&B). Furthermore, concentrations of chemokines including 
lymphocyte-attracting chemokines CCL5 and CXCL10 within the spleens of Ifitm3-/- 
mice were elevated as compared with WT controls (Figure S2C), highlighting that 
tissue lymphopenia was likely not due to impaired chemokine-mediated cellular 
recruitment. Instead, cell death analysis revealed enrichment of late 
apoptotic/necrotic (Annexin V+7AAD+) NK cells (Figure 3C) and CD3+ cells (Figure 
3D) day 4 pi in Ifitm3-/- mice. In contrast, we observed no significant enrichment of 
early apoptotic NK1.1+ or CD3+ cells, as detected by either caspase-3 expression or 
Annexin V+7AAD- staining either 2 or 4 days post-infection (Maria Stacey and Ian 
Humphreys, data not shown). Collectively these data implied that apoptosis-
independent cell death was a significant factor underpinning lymphopenia in MCMV-
infected Ifitm3-/- mice. 
 
 
 
! 10!
Impaired cellular immune responses in MCMV-infected Ifitm3-/- mice 
We examined the influence of cellular immunity on the outcome of MCMV infection in 
Ifitm3-/- mice. Neutrophil depletion exacerbated MCMV-induced weight loss in both 
WT and Ifitm3-/- mice (Figure S2D), consistent with their antiviral function (31) and 
the conclusion that, as suggested by elevated granulocyte responses in Ifitm3-/- mice 
(Figure 3A), impaired neutrophil responses were not responsible for increased 
susceptibility of Ifitm3-/- mice to viral pathogenesis.  
 
NK cells afford critical protection from HCMV (32) and MCMV (2) infections. 
Increased MCMV replication in Ifitm3-/- mice was accompanied by a 5-fold reduction 
in NK cell numbers (Figure 3E) similar to the reduction in splenocytes observed in 
Ifitm3
-/- mice (Figure 3B). This equated to a comparable defect in the accumulation of 
degranulating (CD107a+) and IFN-γ+ cells (Figure 3F) NK cells, although frequencies 
of NK cells spontaneously expressing IFN-γ+ were low in both groups consistent with 
the dominant role of perforin-mediated control of MCMV replication in the spleen 
(33).  This is consistent with the conclusion that Ifitm3 deficiency impinged on 
antiviral NK cell responses by influencing NK cell accumulation and survival rather 
than by directly influencing NK cell function. Notably, NK cell depletion using 
established methodology (34) resulted in comparable virus load in WT and Ifitm3-/- 
mice 4 days pi (Figure 3G), suggesting that the NK cell defect significantly 
contributed to acute MCMV replication and pathology in the Ifitm3-/- mice. In 
accordance, Ifitm3-/- mice did not exhibit impaired control of a strain of MCMV lacking 
the m157 protein (Figure S2E) that specifically induces NK cell activation (35).  
 
During the latter stages of MCMV infection (day 7 pi), in accordance with substantial 
CD3+ cell death at early time-points (Figure 3D), accumulation of CD4+ and CD8+ T 
cell numbers (Figure 3H) and virus-specific CD8+ T cells (Figure 3I) were also 
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drastically reduced in Ifitm3-/- mice, in addition to NK cells (Figure 3H). Therefore, the 
broad protection afforded by Ifitm3 on T cell survival in vivo promoted the generation 
of virus-specific T cell immunity.  
 
Ifitm3 regulates MCMV-induced cytokine production 
Over-exuberant cytokine production is associated with virus-induced lymphopenia 
(30) and with reduced NK cell accumulation during acute MCMV infection (34). We 
therefore hypothesized that unregulated cytokine production was driving loss of 
cellular antiviral immunity in this model. Small but significant elevations of IL-12p70, 
GM-CSF and IFN-α were detected in spleen homogenates from Ifitm3-/- mice (Figure 
4A). We also observed a moderate increase in TNF-α expression d4 pi (Figure 4A), a 
result reproduced in 3 of 4 experiments (data not shown). Importantly, however, 
dramatic increases in IL-6 protein concentrations were routinely observed in Ifitm3-/- 
mice at multiple time-points following acute infection (Figure 4A&B).  
 
IL-6 is implicated in numerous inflammatory pathologies (reviewed in (36)). Therefore 
we investigated the role that IL-6 played in MCMV-associated pathogenesis. Myeloid 
cells (conventional (c)DCs, macrophages and plasmacytoid (p)DCs) were identified 
as primary sources of IL-6 expression during MCMV infection in vivo, and the 
percentage of myeloid cells expressing IL-6 within these populations was 
substantially elevated in Ifitm3-/- mice (Figure 4C). Importantly, MCMV infection of 
chimeric mice expressing Ifitm3 in hematopoietic and/or non-hematopoietic cells 
revealed that hematopoietic cell expression of Ifitm3 was essential for controlled IL-6 
production (Figure 4D). Macrophages, cDCs and pDCs all expressed Ifitm3 during 
MCMV infection (Figure 4E). We therefore hypothesized that Ifitm3 directly inhibited 
virus-induced IL-6 production by myeloid cells. To test this, we generated myeloid 
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cell cultures from WT and Ifitm3-/- bone marrow stem cells. Although Ifitm3 deficiency 
did not impact on low levels of MCMV-induced IL-6 production by M-CSF-
differentiated cells or by MEFs, both GM-CSF- and Flt3L-differentiated Ifitm3-/- cells 
produced significantly more IL-6 than WT cells in response to MCMV (Figure 4F). 
Importantly, these data were derived from the same experiments in which we 
confirmed that Ifitm3 did not restrict MCMV entry (Figure 2).  
 
To further confirm that increased MCMV-induced IL-6 production in Ifitm3-/- myeloid 
cells was not a consequence of enhanced viral replication and/or cell entry, we 
incubated GM-CSF- and Flt3L- differentiated myeloid cells with irradiated MCMV and 
detected increased IL-6 production by Ifitm3-/- cells (Figure 5A&B). Toll like receptors 
(TLRs) 3 and 9 are stimulated by MCMV (37, 38), and Ifitm3-/- myeloid cells also 
produced more IL-6 in response to the TLR9 ligand CpG and, in the case of Flt3L-
generated cells, the TLR3 ligand Poly(I:C) (Figure 5C&D). In contrast, IL-6 induction 
in response to cell surface expressed TLR4 and cytoplasmic DNA sensor STING was 
not significantly altered by Ifitm3 deficiency, although we observed a trend in 
increased IL-6 production following stimulation of both innate immune sensors (Fig. 
S3). Thus, Ifitm3 significantly suppresses myeloid cell regulation of IL-6 production in 
response to endosomal TLR ligands, and replicating and non-replicating MCMV.   
 
IL-6R signaling mediates MCMV-induced pathogenesis  
We assessed whether enhanced cytokine production was responsible for the 
pathogenesis observed in Ifitm3-/- mice. Administration of an antagonist anti-IL-6 
receptor (anti-IL-6R) monoclonal antibody that blocks both classical IL-6 receptor 
signaling and IL-6 trans-signaling in vivo (39) significantly alleviated virus-induced 
weight loss in WT and Ifitm3-/- mice. Here, IL-6R blockade halved the loss of weight 
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in Ifitm3-/- mice seen during the first 4 days of infection (Figure 6A). In contrast, 
neutralization of TNF-α had no impact on MCMV-driven weight loss in Ifitm3-/- mice 
(Figure S4). These data suggested a dominant role for the Ifitm3 regulation of IL-6 
production in determining the pathological outcome of MCMV infection.    
 
Improved outcome of acute infection after anti-IL-6R treatment of Ifitm3-/- mice was 
accompanied by a dramatic reduction in virus replication (4 days pi). The virus load in 
these antibody-treated animals resembled levels observed in infected WT mice 
(Figure 6B). This was associated with a recovery of leukocyte (Figure 6C) and NK 
cell accumulation at this time (Figure 6D&E). Unregulated cytokine production during 
acute MCMV infection promotes NK cell death (34). Interestingly, IL-6R blockade 
completely reversed the accumulation of AnnV+7AAD+ NK cells (Figure 6F). 
Correlation analysis of NK cell accumulation versus PFU of all treated and untreated 
WT and Ifitm3-/- mice revealed a significant inverse correlation between NK cell 
numbers and virus control (Figure 6G), whereas virus load and CD3+ T cells 
accumulation showed no statistically significant correlation (Figure S5A). Thus, 
inhibition of IL-6 receptor signaling alleviates early virus-induced disease in Ifitm3-/- 
hosts. These findings support a role for IL-6 in control of viral replication and NK cell 
survival.  
 
IL-6R signaling is required for the development of antiviral cellular immunity 
The beneficial impact of anti-IL-6R treatment was reduced at later time-points of 
infection in both WT and Ifitm3-/- mice (Figure 6A). IL-6R blockade failed to reverse 
the dramatic loss of T cell accumulation in the spleens of Ifitm3-/- mice 7 days pi 
(Figure 6H) without selectively antagonizing the accumulation of particular 
lymphocyte subsets (Figure S5B). The failure of IL-6R blockade to rescue T cell 
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responses did not reflect a cell-intrinsic role for Ifitm3 in maintaining T cell responses 
in vivo, as demonstrated by comparable recovery of WT and Ifitm3-/- CD4+ and CD8+ 
T cells following MCMV infection (Figure S5C). Instead, in accordance with data 
derived from influenza infection models (40), IL-6 was required for the development 
of virus-specific T cell responses in MCMV (Figure S5D). Furthermore, NK cell 
accumulation at this time was also dependent upon IL-6, and anti-IL-6R treatment 
also failed to rescue the loss of NK cells in Ifitm3-/- mice (Figures 6H and S5B). 
Consequently, the early control of virus replication observed following IL-6R blockade 
in Ifitm3-/- mice was not sustained at 7 days pi (Figure 6I). These data highlight IL-6 
as an important mediator of viral pathogenesis and suggest a critical role for Ifitm3 in 
the appropriate temporal regulation of production of this cytokine in response to 
herpesvirus infection. 
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Discussion 
 
Experimental evidence to date has suggested that exacerbated viral pathogenesis in 
hosts with deficient or impaired IFITM3 activity is a consequence of impaired 
restriction of virus entry and subsequent replication. Herein, we provide evidence that 
direct regulation of virus-induced cytokine production is an important additional in 
vivo function of Ifitm3 and, in the context of CMV infection, represent the dominant 
mechanism through which Ifitm3 controls virus-induced disease.  
 
We demonstrated that the production of multiple cytokines were restricted by Ifitm3. 
However, our data define Ifitm3 regulation of IL-6 production as a central determinant 
of pathogenesis associated with MCMV infection. In the early stages of infection, IL-6 
was the key driver of virus-induced weight loss in WT and Ifitm3-/- mice and impinged 
on cellular antiviral immunity. These findings are consistent with IL-6 driving 
lymphopenia (41), inhibiting lymphopoiesis (42) and inducing glucocorticoid 
expression (43). Further, our data suggests that IL-6-induced apoptosis-independent 
lymphocyte death was associated with lymphopenia in MCMV-infected Ifitm3-/- mice. 
Although it is not possible to discriminate directly ex-vivo between different forms of 
apoptosis-independent cell death, IL-6 may promote cell death directly via induction 
of autophagy (44) or STAT3-mediated necrosis (45). Alternatively, IL-6 may indirectly 
trigger cell death via induction of multiple cytokines implicated in activation-induced 
death of T cells and NK cells (46, 47). Given that IL-6 was also required for the latter 
accumulation of NK cells and virus-specific T cells during MCMV infection, IL-6 likely 
exerts differential context-dependent pro-death or pro-survival signals in leukocytes 
during infection (reviewed in (36)).  
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NK cells exert critical control of HCMV (32) and MCMV (2) infections. Although we 
cannot formally exclude the possibility that Ifitm3 may influence virus replication in an 
unidentified cell type in vivo, the observation that virus load after 4 days of infection 
was comparable in WT and Ifitm3-/- mice following NK cell depletion or after 
challenge with delta-m157 MCMV, strongly suggests that impaired NK cell responses 
was primarily responsible for elevated virus replication in Ifitm3-/- mice. In this regard, 
IL-6R blockade was also found to rescue both NK cell responses and virus control in 
Ifitm3
-/- mice. Interestingly however, although IL-6 has recently been implicated in 
direct control of HCMV replication (48), inhibiting the action of IL-6 restricts HCMV 
reactivation from latency in dendritic cells (49). Thus, it is possible that the beneficial 
impact of anti-IL-6R treatment on control of virus replication in our experiments may 
extend beyond restriction of lymphopenia and NK cell death.  
 
Ifitm3 restricted myeloid cell production of IL-6 upon exposure to MCMV in vitro. 
Ifitm3 expression by hematopoietic cells was critical for controlled production of IL-6 
in vivo, and frequencies of IL-6-secreting myeloid cells were elevated in MCMV-
infected Ifitm3-/- mice. The latter observation may reflect in part a feedback 
mechanism through which elevated virus load in Ifitm3-/- mice further stimulated 
myeloid cell production of IL-6 and hence increases the frequency of myeloid cells 
capable of producing IL-6 ex-vivo. Critically, however, we demonstrate that Ifitm3-/- 
myeloid cells produced more IL-6 in response to non-replicating virus, and IL-6R 
blockade is sufficient to restore control of MCMV replication in Ifitm3-/- mice. Thus, 
Ifitm3 acts as an immune regulator that restricts virus-induced IL-6 production by 
myeloid cells independently of controlling virus entry and replication. The Ifitm3-IL-6 
axis is therefore responsible for determining viral pathogenesis in vivo.  
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TLRs located in endosomes are triggered by MCMV (37, 38) and induce expression 
of cytokines including IL-6 upon stimulation (50). Critically, our data reveal that Ifitm3 
suppresses TLR3 and TLR9-induced cytokine production by myeloid cells in 
response to non-replicating ligands. In contrast, IL-6 production by Ifitm3-/- cells was 
only moderately elevated following stimulation of cell membrane-expressed TLR4 or 
the cytoplasmic DNA sensor STING. These data suggest that Ifitm3 may 
preferentially regulate the activation and/or down-stream signaling triggered by 
endosomal TLRs, and that this represents a broad regulatory function not restricted 
to antiviral responses. IFITM3 localization within endosomes may be critical for its 
regulatory function either directly or by influencing the entry of virus, TLR ligands or 
TLR receptors into the endosomal pathway. Importantly, however, a trend of 
increased cytokine expression in response to STING and TLR4 ligands also 
suggests that the regulatory function(s) of IFITM3 extend beyond modulation of 
endosomal TLR activation. A role for IFITM3 in membrane trafficking has been 
reported (51) and thus IFITM3 may influence downstream events induced by innate 
pathogen recognition such as expression or secretion of cytokines and/or the activity 
of cytokine receptors. Understanding the exact function of IFITM3 within virus-
exposed, virus-infected and uninfected cells clearly represents an important future 
area of study. 
 
Overt cytokine production observed in MCMV-infected Ifitm3-/- mice displayed some 
similarities to the inflammatory disease hemophagocytic lymphohistiocytosis (HLH). 
Herpesvirus infections, particularly Epstein Barr virus (EBV), are common triggers of 
HLH, and EBV-associated HLH is highly prevalent in Asia suggesting an influence of 
host genetics on disease (52). Our data imply that genetic variation in genes 
encoding proteins such as IFITM3 that exhibit immune modulatory functions may 
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influence the occurrence and/or severity of herpesvirus-triggered HLH. The data 
derived from our in vivo model also imply that individuals with the minor IFITM3 
rs12252-C SNP may also have altered susceptibility to HCMV disease.  
 
An important implication of our data is that individuals with reduced IFITM3 activity 
suffer from virus-induced pathogenesis that is driven, at least part, by unregulated 
cytokine production. In support of this hypothesis, heightened early production of 
inflammatory-associated cytokines including IL-6 is associated with the fatal outcome 
of influenza H7N9 infection (53), consistent with a role for inflammation in driving 
influenza-associated diseases (54-56). Critically, Wang et al demonstrated the 
rs12252-C SNP as a concurrent risk factor of fatal influenza infection (53). We now 
provide direct evidence of a link between excessive cytokine production as a 
consequence of impaired IFITM3 function and fatal viral infection. 
 
Overall, our data demonstrate that restriction of virus-induced cytokine production is 
an important and previously unexplored mechanism through which IFITM3 regulates 
both virus-induced pathogenesis, and that this process exerts a critical influence on 
the outcome of cytomegalovirus infection. Although the long-term benefits of IL-6R 
blockade were limited due to the latter requirement of this cytokine pathway in 
cellular immune responses including the development of virus-specific T cell 
immunity, these results highlight that reducing overt cytokine production, perhaps 
using more subtle and/or broader approaches, may represent an effective strategy 
for the treatment of virus-infected individuals with impaired IFITM3 activity. Finally, 
the discovery that IFITM3 inhibits TLR-mediated cytokine production may provide 
insight into why the rs12252-C SNP has been conserved in human population 
despite its potential deleterious effect associated with reduced IFITM3 function. 
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Methods 
 
Mice, viral infections and treatments 
Ifitm3-deficient (Ifitm3-/-) and WT controls (95% C57BL/6, 5% 129) have been 
previously described (16). Age- and sex-matched mice between 7-12 weeks were 
used in experiments. MCMV Smith strain (ATCC) for in vivo experimentation was 
prepared in salivary glands of 3-4 week old BALB/c mice. Salivary glands were 
homogenized and virus from supernatant purified over a sorbital gradient. Virus was 
passaged no less than 3 and no more than 5 times in vivo. Virus from homogenized 
organs and tissue culture supernatants were titered for 6 days on 3T3 cells with a 
carboxymethylcellulose overlay. Mice were infected intraperitoneally (i.p.) with 3 × 
104 PFU MCMV. For NK cell depletion, mice were injected i.p. with 200μg αNK1.1 
(clone PK136, BioXCell) or IgG control on days −2, 0, and +2 pi, or in repeat 
experiments were injected i.p with 250μg αAsialo-GM1 (polyclonal antibody, 
eBioscience) or PBS control on days -3 and 0 pi. For IL-6R blockade, mice were 
injected i.p with 300μg αIL-6R (clone 2B10 or IgG control on day 0, and for 7-day 
experiments, on day 4 pi. For WT/Ifitm3-/- bone marrow chimeras, mice were 
irradiated at 2 x 4.5 Gy and transfused intra-venous (i.v) with 1 x 106 bone marrow 
cells 24 hours later. Mice were then treated for 2 weeks with antibiotic supplemented 
water. Mice were infected with MCMV 8 weeks after irradiation.  
 
Leukocyte isolation, intracellular cytokine staining, and flow cytometry 
Leukocytes (1 x 106) were stained, in most experiments, with Zombie Aqua dye, 
incubated with Fc block (both from Biolegend) and stained for surface markers with a 
combination of the following antibodies (all from Biolegend, eBioscience or BD 
Biosciences): αNK1.1 (clone PK136), αCD3ε (Clone 145-2C11), αCD25 (Clone 3C7) 
αCD4 (Clone GK1.5), αCD8 (Clone 53-6.7), αCD11b (clone M1/70), αCD11c (clone 
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N418), αCD45R/B220 (clone RA3-6B2), αF4/80 (clone BM8), αI-A/I-E (clone 
M5/114.15.2), αLy6G (clone 1A8), and αSiglec H (clone 551). Following surface 
staining, some cells were fixed and permeabilized with saponin buffer (PBS, 2% 
FCS, 0.05% sodium azide, and 0.5% saponin) and stained with αIL-6 (clone MP5-
20F3, Biolegend), or rabbit polyclonal αIFITM3 (Abcam) followed by αrabbit-PE 
(Sigma-Aldrich). For analysis of NK cell function, cells were incubated for 5 hours in 
monensin (BD Pharmingen) and αCD107a (clone 1D4B, Biolegend), stained with 
αNK1.1 and αCD3ε, permeabilized and then stained with αIFN-γ (clone XMG1.2, 
Biolegend). Other unfixed cell preparations were stained with 7AAD and Annexin V 
(both Biolegend). M45-specific CD8 T cell responses (57) and functional NK cell 
responses were assessed as described previously (34).  
 
At least 20,000 leukocytes were analyzed using a BD FACSCanto II flow cytometer 
(BD Biosciences). Electronic compensation was performed with Ab capture beads 
stained separately with individual mAbs used in the experimental panel. Data were 
analyzed using FlowJo software version 8.5.3 (Tree Star). Total numbers of different 
cell populations were calculated by multiplying the total number of viable leukocytes 
(assessed by trypan blue exclusion) by percent positive cells, as detected by flow 
cytometry. 
 
Peripheral leukocytes, platelet and red blood cell assessment 
Small (50 μl) blood samples were collected from the lateral tail vein into K2 EDTA-
coated 0.1 ml paediatric tubes with an integrated capillary (Kabe Labortechnik 
GmbH) for complete blood counts determination using a Scil Vetabc system. 
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In vitro infections 
Bone marrow cells were incubated at 2 x 105 cells/ml or 4 x 105 cells/ml in media 
supplemented with 20ng/ml of M-CSF (Biolegend) or with 50µM 2-Mercaptoethanol 
(Gibco) and 20ng/ml of GM-CSF (Biolegend) for 7 days, respectively. Media was 
replenished after 3 days. For bone-marrow derived Flt3-Ligand (Flt3L) induced 
myeloid cells, cells were incubated a 4 x 105 cells/ml in R10 media supplemented 
with 50µM 2-Mercaptoethanol and 100ng/ml of Flt3L (Biolegend) for 9 days, 
replenishing media on days 4 and day 8. Myeloid cells were then mock infected or 
infected with MCMV (pSM3fr-MCK-2fl, a kind gift from Chris Benedict and Barbara 
Adler) at an MOI of 1 or 0.1. Some cells were incubated with pSM3fr-MCK-2fl that 
was irradiated (2520Gy) and confirmed as replication deficient by failed infection of 
3T3 cells. Some cells were treated with 80µM EIPA (Sigma-Aldrich) 30 minutes prior 
to infection whereas others were treated with 10µg/ml Poly(I:C) (Sigma-Aldrich) or 
CpG ODN2395 or ODN2395 control (ODN5328) (Miltenyi). After 6 or 24 hours, 
supernatants were collected for IL-6 protein analysis.  
 
To quantify virus infection, M-CSF and GM-CSF generated myeloid cells were 
infected with pSM3fr-MCK-2fl MCMV (MOI of 1 or 0.1), and 24hrs later cells stained 
with Zombie Aqua dye and FC block, stained for surface markers as described above 
prior to fixation and permeabilization and intracellular staining with anti-m06 antibody 
(CapRi) conjugated with APC (Innova Biosciences). Some cells were incubated for 4 
days and supernatant analyzed for infectious virus by plaque assay. 
 
To generate primary fibroblasts, adult Ifitm3-/- mice were intercrossed and MEFs were 
derived from embryos at day 13.5 of gestation, as described previously (13). MEFs 
were cultured in DMEM, containing 10% FBS, 1X MEM essential amino acids, 1X 2-
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Mercaptoethanol (Gibco). MEFs were then infected with MCMV as above and 
replicating virus in the supernatant quantified by plaque assay 4 days later. 
 
Cytokine and chemokine analysis 
IL-6 protein was measured by ELISA (Biolegend). Pro-inflammatory cytokines were 
measured using a ProcartaPlex Multiplex Immunoassay kit (eBioscience) and run on 
a Bio-Plex 200 luminex machine (Biorad). 
 
Histology 
For histological examination tissues of MCMV-infected tissues, organs were fixed in 
4% formaldehyde and then processed to paraffin blocks. 5μm sections of paraffin-
embedded tissue were stained with haematoxylin and eosin (Sigma-Aldrich). 
 
Statistics 
For viral load analysis, statistical significance was determined using the Mann-
Whitney U test for comparing WT with Ifitm3-/- groups. To analyze viral load data from 
multiple groups given different treatments, data were first subjected to logarithmic 
transformation and subsequent two-way ANOVA analysis was performed. For paired 
analysis of flow cytometry data and ELISA data, the two-tailed Student’s t test was 
used for paired data sets, and 1-way ANOVA adopted for analysis of data derived 
from >2 groups of mice, including grouped weight loss data. *p<0.05, **p<0.01, 
***p<0.001. 
 
Study Approval 
All animal studies were performed at the Wellcome Trust Sanger Institute research 
support facility under UK Home Office Project License number 80/2596. 
! 23!
Author Contributions 
M.A.S., S.C., M.M., MC., C.A.F., S.E.S., R.S.W., S.G.B., G.S., L.K., K.H., C.B., G.N., 
E.L.C., C.I., A.O.S. and I.R.H. conducted the experiments. M.A.S., S.C., C.A.F., 
A.O.S., Z.J., W.F., S.A.J., P.K. and I.R.H. designed the experiments, and analyzed 
and interpreted the data. Z.J. and W.F. provided key reagents. M.A.S., S.C., S.A.J., 
P.K., and I.R.H. wrote the manuscript. 
 
 
Acknowledgements 
The authors wish to thank Professor Gordon Dougan for helpful input and for 
facilitating WTSI-based studies, and Professors Gavin Wilkinson and Awen Gallimore 
for critical discussion. The authors are grateful to Drs Chris Benedict and Alec 
Redwood for the provision of K181 and delta m157 viruses. This study was funded 
by a Wellcome Trust Senior Research Fellowship in Basic Science (to IRH), a Cardiff 
University President’s Scholarship Studentship (to GS), an MRC-DTG (to SGB) and 
Wellcome Trust grant 098051 (to WTSI investigators). 
 
 
 
 
 
 
 
 
 
 
! 24!
References 
 
1. van Dommelen SL, Sumaria N, Schreiber RD, Scalzo AA, Smyth MJ, and 
Degli-Esposti MA. Perforin and granzymes have distinct roles in defensive 
immunity and immunopathology. Immunity. 2006;25(5):835-48. 
2. Bukowski JF, Woda BA, and Welsh RM. Pathogenesis of murine 
cytomegalovirus infection in natural killer cell-depleted mice. J Virol. 
1984;52(1):119-28. 
3. Presti RM, Pollock JL, Dal Canto AJ, O'Guin AK, and Virgin HWt. Interferon 
gamma regulates acute and latent murine cytomegalovirus infection and 
chronic disease of the great vessels. J Exp Med. 1998;188(3):577-88. 
4. Jackson SE, Mason GM, and Wills MR. Human cytomegalovirus immunity 
and immune evasion. Virus Res. 2011;157(2):151-60. 
5. Powers C, DeFilippis V, Malouli D, and Fruh K. Cytomegalovirus immune 
evasion. Curr Top Microbiol Immunol. 2008;325(333-59. 
6. Weekes MP, Tomasec P, Huttlin EL, Fielding CA, Nusinow D, Stanton RJ, 
Wang EC, Aicheler R, Murrell I, Wilkinson GW, et al. Quantitative temporal 
viromics: an approach to investigate host-pathogen interaction. Cell. 
2014;157(6):1460-72. 
7. Mandaric S, Walton SM, Rulicke T, Richter K, Girard-Madoux MJ, Clausen 
BE, Zurunic A, Kamanaka M, Flavell RA, Jonjic S, et al. IL-10 suppression of 
NK/DC crosstalk leads to poor priming of MCMV-specific CD4 T cells and 
prolonged MCMV persistence. PLoS Pathog. 2012;8(8):e1002846. 
8. Stack G, Jones E, Marsden M, Stacey MA, Snelgrove RJ, Lacaze P, Jacques 
LC, Cuff SM, Stanton RJ, Gallimore AM, et al. CD200 receptor restriction of 
myeloid cell responses antagonizes antiviral immunity and facilitates 
cytomegalovirus persistence within mucosal tissue. PLoS Pathog. 
2015;11(2):e1004641. 
! 25!
9. Humphreys IR, de Trez C, Kinkade A, Benedict CA, Croft M, and Ware CF. 
Cytomegalovirus exploits IL-10-mediated immune regulation in the salivary 
glands. J Exp Med. 2007;204(5):1217-25. 
10. Oakley OR, Garvy BA, Humphreys S, Qureshi MH, and Pomeroy C. 
Increased weight loss with reduced viral replication in interleukin-10 knock-
out mice infected with murine cytomegalovirus. Clin Exp Immunol. 
2008;151(1):155-64. 
11. Chang WL, and Barry PA. Attenuation of innate immunity by cytomegalovirus 
IL-10 establishes a long-term deficit of adaptive antiviral immunity. Proc Natl 
Acad Sci U S A. 2010;107(52):22647-52. 
12. Bailey CC, Zhong G, Huang IC, and Farzan M. IFITM-Family Proteins: The 
Cell's First Line of Antiviral Defense. Annu Rev Virol. 2014;1(261-83. 
13. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, Ryan BJ, 
Weyer JL, van der Weyden L, Fikrig E, et al. The IFITM proteins mediate 
cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue 
virus. Cell. 2009;139(7):1243-54. 
14. Lu J, Pan Q, Rong L, He W, Liu SL, and Liang C. The IFITM proteins inhibit 
HIV-1 infection. J Virol. 2011;85(5):2126-37. 
15. John SP, Chin CR, Perreira JM, Feeley EM, Aker AM, Savidis G, Smith SE, 
Elia AE, Everitt AR, Vora M, et al. The CD225 domain of IFITM3 is required 
for both IFITM protein association and inhibition of influenza A virus and 
dengue virus replication. J Virol. 2013;87(14):7837-52. 
16. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, Chin CR, Feeley 
EM, Sims JS, Adams DJ, et al. IFITM3 restricts the morbidity and mortality 
associated with influenza. Nature. 2012;484(7395):519-23. 
17. Zhang YH, Zhao Y, Li N, Peng YC, Giannoulatou E, Jin RH, Yan HP, Wu H, 
Liu JH, Liu N, et al. Interferon-induced transmembrane protein-3 genetic 
! 26!
variant rs12252-C is associated with severe influenza in Chinese individuals. 
Nat Commun. 2013;4(1418. 
18. Chesarino NM, McMichael TM, Hach JC, and Yount JS. Phosphorylation of 
the antiviral protein interferon-inducible transmembrane protein 3 (IFITM3) 
dually regulates its endocytosis and ubiquitination. J Biol Chem. 
2014;289(17):11986-92. 
19. Zhang Y, Makvandi-Nejad S, Qin L, Zhao Y, Zhang T, Wang L, Repapi E, 
Taylor S, McMichael A, Li N, et al. Interferon-induced transmembrane protein-
3 rs12252-C is associated with rapid progression of acute HIV-1 infection in 
Chinese MSM cohort. AIDS. 2015;29(8):889-94. 
20. Bailey CC, Huang IC, Kam C, and Farzan M. Ifitm3 limits the severity of acute 
influenza in mice. PLoS Pathog. 2012;8(9):e1002909. 
21. Poddar S, Hyde JL, Gorman MJ, Farzan M, and Diamond MS. The Interferon-
Stimulated Gene IFITM3 Restricts Infection and Pathogenesis of Arthritogenic 
and Encephalitic Alphaviruses. J Virol. 2016;90(19):8780-94. 
22. Everitt AR, Clare S, McDonald JU, Kane L, Harcourt K, Ahras M, Lall A, Hale 
C, Rodgers A, Young DB, et al. Defining the range of pathogens susceptible 
to Ifitm3 restriction using a knockout mouse model. PLoS One. 
2013;8(11):e80723. 
23. Gorman MJ, Poddar S, Farzan M, and Diamond MS. The Interferon-
Stimulated Gene Ifitm3 Restricts West Nile Virus Infection and Pathogenesis. 
J Virol. 2016;90(18):8212-25. 
24. Infusini G, Smith JM, Yuan H, Pizzolla A, Ng WC, Londrigan SL, Haque A, 
Reading PC, Villadangos JA, and Wakim LM. Respiratory DC Use IFITM3 to 
Avoid Direct Viral Infection and Safeguard Virus-Specific CD8+ T Cell 
Priming. PLoS One. 2015;10(11):e0143539. 
! 27!
25. Wakim LM, Gupta N, Mintern JD, and Villadangos JA. Enhanced survival of 
lung tissue-resident memory CD8(+) T cells during infection with influenza 
virus due to selective expression of IFITM3. Nat Immunol. 2013;14(3):238-45. 
26. Warren CJ, Griffin LM, Little AS, Huang IC, Farzan M, and Pyeon D. The 
antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human 
papillomavirus, cytomegalovirus and adenovirus. PLoS One. 
2014;9(5):e96579. 
27. Xie M, Xuan B, Shan J, Pan D, Sun Y, Shan Z, Zhang J, Yu D, Li B, and Qian 
Z. Human cytomegalovirus exploits interferon-induced transmembrane 
proteins to facilitate morphogenesis of the virion assembly compartment. J 
Virol. 2015;89(6):3049-61. 
28. Ryckman BJ, Jarvis MA, Drummond DD, Nelson JA, and Johnson DC. 
Human cytomegalovirus entry into epithelial and endothelial cells depends on 
genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol. 
2006;80(2):710-22. 
29. Rice GP, Schrier RD, and Oldstone MB. Cytomegalovirus infects human 
lymphocytes and monocytes: virus expression is restricted to immediate-early 
gene products. Proc Natl Acad Sci U S A. 1984;81(19):6134-8. 
30. Tumpey TM, Lu X, Morken T, Zaki SR, and Katz JM. Depletion of 
lymphocytes and diminished cytokine production in mice infected with a 
highly virulent influenza A (H5N1) virus isolated from humans. J Virol. 
2000;74(13):6105-16. 
31. Stacey MA, Marsden M, Pham NT, Clare S, Dolton G, Stack G, Jones E, 
Klenerman P, Gallimore AM, Taylor PR, et al. Neutrophils recruited by IL-22 
in peripheral tissues function as TRAIL-dependent antiviral effectors against 
MCMV. Cell Host Microbe. 2014;15(4):471-83. 
32. Biron CA, Byron KS, and Sullivan JL. Severe herpesvirus infections in an 
adolescent without natural killer cells. N Engl J Med. 1989;320(26):1731-5. 
! 28!
33. Loh J, Chu DT, O'Guin AK, Yokoyama WM, and Virgin HWt. Natural killer 
cells utilize both perforin and gamma interferon to regulate murine 
cytomegalovirus infection in the spleen and liver. J Virol. 2005;79(1):661-7. 
34. Stacey MA, Marsden M, Wang EC, Wilkinson GW, and Humphreys IR. IL-10 
restricts activation-induced death of NK cells during acute murine 
cytomegalovirus infection. J Immunol. 2011;187(6):2944-52. 
35. Parikh BA, Piersma SJ, Pak-Wittel MA, Yang L, Schreiber RD, and 
Yokoyama WM. Dual Requirement of Cytokine and Activation Receptor 
Triggering for Cytotoxic Control of Murine Cytomegalovirus by NK Cells. 
PLoS Pathog. 2015;11(12):e1005323. 
36. Hunter CA, and Jones SA. IL-6 as a keystone cytokine in health and disease. 
Nat Immunol. 2015;16(5):448-57. 
37. Krug A, French AR, Barchet W, Fischer JA, Dzionek A, Pingel JT, Orihuela 
MM, Akira S, Yokoyama WM, and Colonna M. TLR9-dependent recognition 
of MCMV by IPC and DC generates coordinated cytokine responses that 
activate antiviral NK cell function. Immunity. 2004;21(1):107-19. 
38. Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K, Mudd S, Shamel 
L, Sovath S, Goode J, et al. Toll-like receptors 9 and 3 as essential 
components of innate immune defense against mouse cytomegalovirus 
infection. Proc Natl Acad Sci U S A. 2004;101(10):3516-21. 
39. Lissilaa R, Buatois V, Magistrelli G, Williams AS, Jones GW, Herren S, Shang 
L, Malinge P, Guilhot F, Chatel L, et al. Although IL-6 trans-signaling is 
sufficient to drive local immune responses, classical IL-6 signaling is obligate 
for the induction of T cell-mediated autoimmunity. J Immunol. 
2010;185(9):5512-21. 
40. Lauder SN, Jones E, Smart K, Bloom A, Williams AS, Hindley JP, Ondondo 
B, Taylor PR, Clement M, Fielding C, et al. Interleukin-6 limits influenza-
! 29!
induced inflammation and protects against fatal lung pathology. Eur J 
Immunol. 2013;43(10):2613-25. 
41. Ulich TR, del Castillo J, and Guo KZ. In vivo hematologic effects of 
recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs 
and WBCs. Blood. 1989;73(1):108-10. 
42. Maeda K, Baba Y, Nagai Y, Miyazaki K, Malykhin A, Nakamura K, Kincade 
PW, Sakaguchi N, and Coggeshall KM. IL-6 blocks a discrete early step in 
lymphopoiesis. Blood. 2005;106(3):879-85. 
43. Ruzek MC, Miller AH, Opal SM, Pearce BD, and Biron CA. Characterization 
of early cytokine responses and an interleukin (IL)-6-dependent pathway of 
endogenous glucocorticoid induction during murine cytomegalovirus infection. 
J Exp Med. 1997;185(7):1185-92. 
44. Xue H, Yuan G, Guo X, Liu Q, Zhang J, Gao X, Guo X, Xu S, Li T, Shao Q, et 
al. A novel tumor-promoting mechanism of IL6 and the therapeutic efficacy of 
tocilizumab: Hypoxia-induced IL6 is a potent autophagy initiator in 
glioblastoma via the p-STAT3-MIR155-3p-CREBRF pathway. Autophagy. 
2016;12(7):1129-52. 
45. He Y, Fisher R, Chowdhury S, Sultana I, Pereira CP, Bray M, and Reed JL. 
Vaccinia virus induces rapid necrosis in keratinocytes by a STAT3-dependent 
mechanism. PLoS One. 2014;9(11):e113690. 
46. von Rossum A, Krall R, Escalante NK, and Choy JC. Inflammatory cytokines 
determine the susceptibility of human CD8 T cells to Fas-mediated activation-
induced cell death through modulation of FasL and c-FLIP(S) expression. J 
Biol Chem. 2011;286(24):21137-44. 
47. Ross ME, and Caligiuri MA. Cytokine-induced apoptosis of human natural 
killer cells identifies a novel mechanism to regulate the innate immune 
response. Blood. 1997;89(3):910-8. 
! 30!
48. Harwardt T, Lukas S, Zenger M, Reitberger T, Danzer D, Ubner T, Munday 
DC, Nevels M, and Paulus C. Human Cytomegalovirus Immediate-Early 1 
Protein Rewires Upstream STAT3 to Downstream STAT1 Signaling Switching 
an IL6-Type to an IFNgamma-Like Response. PLoS Pathog. 
2016;12(7):e1005748. 
49. Reeves MB, and Compton T. Inhibition of inflammatory interleukin-6 activity 
via extracellular signal-regulated kinase-mitogen-activated protein kinase 
signaling antagonizes human cytomegalovirus reactivation from dendritic 
cells. J Virol. 2011;85(23):12750-8. 
50. Takeda K, and Akira S. Toll-like receptors in innate immunity. Int Immunol. 
2005;17(1):1-14. 
51. Wee YS, Roundy KM, Weis JJ, and Weis JH. Interferon-inducible 
transmembrane proteins of the innate immune response act as membrane 
organizers by influencing clathrin and v-ATPase localization and function. 
Innate Immun. 2012;18(6):834-45. 
52. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu 
Rev Med. 2012;63(233-46. 
53. Wang Z, Zhang A, Wan Y, Liu X, Qiu C, Xi X, Ren Y, Wang J, Dong Y, Bao 
M, et al. Early hypercytokinemia is associated with interferon-induced 
transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. 
Proc Natl Acad Sci U S A. 2014;111(2):769-74. 
54. Hussell T, Pennycook A, and Openshaw PJ. Inhibition of tumor necrosis 
factor reduces the severity of virus-specific lung immunopathology. Eur J 
Immunol. 2001;31(9):2566-73. 
55. Humphreys IR, Walzl G, Edwards L, Rae A, Hill S, and Hussell T. A critical 
role for OX40 in T cell-mediated immunopathology during lung viral infection. 
J Exp Med. 2003;198(8):1237-42. 
! 31!
56. Sun J, Madan R, Karp CL, and Braciale TJ. Effector T cells control lung 
inflammation during acute influenza virus infection by producing IL-10. Nat 
Med. 2009;15(3):277-84. 
57. Jones M, Ladell K, Wynn KK, Stacey MA, Quigley MF, Gostick E, Price DA, 
and Humphreys IR. IL-10 restricts memory T cell inflation during 
cytomegalovirus infection. J Immunol. 2010;185(6):3583-92. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! 32!
Figure Legends 
 
Figure 1. Ifitm3 affords critical protection from MCMV infection. WT and Ifitm3-/- 
mice were infected with 3x104 PFU MCMV, and survival (A) and weight loss (B) were 
assessed over time. Survival data includes mice culled according to UK Home Office 
restrictions of virus-induced weight loss. Data from 14 (WT) and 21 (Ifitm3-/-) 
mice/group merged from 3 experiments is shown. Replicating virus in spleens (C), 
lung (D), liver (E) and salivary glands (F) day 4 (C-E) or 14 (F) post-infection was 
quantified by plaque assay. (G) Spleen morphology in WT and Ifitm3-/- mice 14 days 
pi. (H) Spleens were taken 14 days pi and sections stained with H&E. Magnification = 
20x, scale bars = 10mm. Data is representative of at least 3 separate experiments. 
 
Figure 2. Ifitm3 does not restrict MCMV replication. Mixed WT/Ifitm3-/- bone 
marrow chimeras were generated and infected with MCMV, and after 4 days PFU in 
spleen (A) and lung (B) were measured. Individual mice + median are shown from 
one of two experiments. M-CSF (C&D), GM-CSF (E&F) and Flt3L (G&H) 
differentiated myeloid cells derived from WT and Ifitm3-/- bone marrow, and WT and 
Ifitm3-/- MEFs (I&J) were infected with MCMV (pSM3fr-MCK-2fl) at different MOIs and 
MCMV m06 protein was detected 24hrs later by flow cytometry. Data represents 2-3 
experiments and panels B, D, F & H show mean + SEM of quadruplet wells. (K) WT 
and Ifitm3-/- MEFs, M-CSF, GM-CSF and Flt3L differentiated myeloid cells were 
infected with pSM3fr-MCK-2fl MCMV at an MOI=1 and supernatant taken 4 days 
later and replicating virus quantified by plaque assay. Results are representative of 
2-4 experiments. 
 
 
Figure 3. Ifitm3 deficiency leads to an impairment of cellular immunity. WT and 
Ifitm3-/- mice were infected with MCMV. (A) On days 0, 2 and 4, frequencies of 
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circulating leukocyte populations in blood were quantified. Mean + SEM of 3 
mice/group is shown and represents 3 experiments. (B) Viable splenocytes were 
quantified d4 pi. Mean + SEM of 3-9 mice per group is shown and represents at least 
5 experiments. NK1.1+CD3- cells (C) and CD3+ cells (D) were stained with 7AAD and 
Annexin V. Mean + SEM of 4-6 mice per group is shown and represents at least 3 
experiments. (E) Representative bivariate flow plots of NK1.1 versus CD3, gated on 
viable cells (left), and total viable NK cells (right) D4 pi. Mean + SEM of 3-9 mice per 
group is shown and represents at least 5 experiments. (F) Total numbers of NK cells 
positive for CD107a or intracellular IFNg were quantified by flow cytometry at d4 pi. 
Mean + SEM of 8-9 mice/group is shown and represents 3 experiments. (G) WT and 
Ifitm3-/- mice were depleted of NK cells and splenic virus load assessed by plaque 
assay 4 days later. Individual mice + median is shown and represents 3 experiments 
(2 using aNK1.1 and 1 using aASGM1 treatment). (H) Numbers of CD4+ cells, CD8+ 
cells and NK1.1+ cells were quantified in the spleen d7 pi. Individual mice + mean are 
shown and represent 3 similar experiments. (I) % and total M45-specific CD8+ T cells 
7 pi. All results represent at least 3 experiments.  
 
Figure 4. Ifitm3 suppresses MCMV-induced IL-6 production. (A-C) WT and 
Ifitm3
-/- mice were infected or not with MCMV. (A) Pro-inflammatory cytokines 
were measured by multiplex immunoassay in spleen homogenates 4 days pi. Mean 
values + SEM of 8-9 mice/group are shown. (B) Spleens were taken on days 0, 2 
and 4 days pi and IL-6 measured by ELISA in tissue homogenates. Individual mice + 
mean values are depicted and data represent at least 2 experiments at each time 
point. (C) IL-6 expression by (unstimulated ex-vivo) CD11chiMHCII+ (cDCs), CD11b-
CD11c+B220+SiglecH+ (pDCs) and F4/80+CD11b+ (macs) was detected by flow 
cytometry. Mean + SEM of expression values from 4-5 mice/group is shown and 
represents 2 experiments. (D) Mixed WT/Ifitm3-/- bone marrow chimeras were 
generated and infected with MCMV. After 4 days, IL-6 in spleen supernatants was 
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quantified by ELISA. Data from one of two experiments is shown. (E) Ifitm3 
expression by splenic macrophages (macs), cDCs and pDCs was assessed by flow 
cytometry (blue line = WT at day 0, green line = WT at day 2 pi, red line = Ifitm3-/- at 
day 2 pi). (F) WT and Ifitm3-/- Flt3L-, GM-CSF- and M-CSF-generated myeloid cells 
and primary MEFs were infected with pSM3fr-MCK-2fl MCMV (MOI=1) and IL-6 
protein measured 6 hours later. Mean + SEM of 4 quadruplet wells are shown. Data 
represents at least 3 experiments. 
 
Figure 5. Ifitm3-/- myeloid cells are hyper-responsive to replication deficient 
virus and endosomal TLR ligand stimulation. (A&B) GM-CSF and Flt3L 
differentiated myeloid cells were infected or not with irradiated MCMV and IL-6 
protein in the supernatants was analyzed by ELISA 24 hours later. (C&D) GM-CSF 
and Flt3L differentiated myeloid cells were stimulated or not with a control CPG or 
CPG (both 0.5mg/ml) or Poly(I:C) (10mg/ml) for 24 hours and IL-6 protein in the 
supernatants was then analyzed by ELISA. Mean + SEM of quadruplet wells are 
shown and represent 2 (C&D) or 3 (A&B) experiments. 
 
Figure 6. IL-6 is a critical regulator of MCMV-induced pathology in Ifitm3-/- mice. 
WT and Ifitm3-/- mice were infected with 3x104 PFU MCMV and treated with IgG or 
anti-IL-6R (2B10) on days 0 and 4 pi. (A) Weight loss was measured over a 7-day 
time course. Mean + SEM of 4-11 mice/group is shown. (B) Virus load in the spleen 
was quantified by plaque assay at 4 days pi. Individual mice + median are shown and 
represents 2 experiments. (C) Viable splenocytes were counted on day 4 pi. Mean + 
SEM are shown of 2 merged experiments containing 9-11 mice/group. (D) 
Representative bivariate plots of NK1.1 versus CD3 expression in WT (left) and 
Ifitm3-/- (right) mice 4 days pi after IgG (top) or anti-IL-6R (bottom) treatment. Viable 
NK cells (E) and Annexin V+7AAD+ NK cells (F) were quantified at 4 days pi. (G) 
Correlation between virus load and NK1.1+CD3- cells in WT/Ifitm3-/- mice treated with 
! 35!
IgG or anti-IL-6R. (H&I) After 7 days, viable splenic T cell and NK1.1+ cells were 
quantified and expressed as mean + SEM from 4-6 mice/group, (H) and virus load in 
the spleen was measured (I). All results represent 2-3 experiments.  
 
 
 
 
 
 
 
 
 






